
Anita K Dunbier

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9393999/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study. Journal of Clinical Oncology, 2010, 28, 1829-1834.	0.8	647
2	Comparison of PAM50 Risk of Recurrence Score With Onco <i>type</i> DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy. Journal of Clinical Oncology, 2013, 31, 2783-2790.	0.8	557
3	Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nature Genetics, 2000, 26, 16-17.	9.4	420
4	Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncology, The, 2013, 14, 1067-1076.	5.1	332
5	ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer. Cancer Discovery, 2011, 1, 338-351.	7.7	284
6	Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer. Clinical Cancer Research, 2008, 14, 8019-8026.	3.2	220
7	Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance. Clinical Cancer Research, 2013, 19, 2775-2786.	3.2	119
8	Destabilized Adhesion in the Gastric Proliferative Zone and c-Src Kinase Activation Mark the Development of Early Diffuse Gastric Cancer. Cancer Research, 2007, 67, 2480-2489.	0.4	114
9	Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer. Journal of Clinical Oncology, 2015, 33, 2270-2278.	0.8	96
10	Relationship Between Plasma Estradiol Levels and Estrogen-Responsive Gene Expression in Estrogen Receptor–Positive Breast Cancer in Postmenopausal Women. Journal of Clinical Oncology, 2010, 28, 1161-1167.	0.8	94
11	A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance. Clinical Cancer Research, 2011, 17, 2024-2034.	3.2	88
12	Endocrine Therapy, New Biologicals, and New Study Designs for Presurgical Studies in Breast Cancer. Journal of the National Cancer Institute Monographs, 2011, 2011, 120-123.	0.9	69
13	Fatty acid oxidation is associated with proliferation and prognosis in breast and other cancers. BMC Cancer, 2018, 18, 805.	1.1	65
14	Exploring Breast Cancer Estrogen Disposition: The Basis for Endocrine Manipulation. Clinical Cancer Research, 2011, 17, 4948-4958.	3.2	58
15	Association between breast cancer subtypes and response to neoadjuvant anastrozole. Steroids, 2011, 76, 736-740.	0.8	48
16	ESR1 Is Co-Expressed with Closely Adjacent Uncharacterised Genes Spanning a Breast Cancer Susceptibility Locus at 6q25.1. PLoS Genetics, 2011, 7, e1001382.	1.5	47
17	Substrate binding allosterically relieves autoinhibition of the pseudokinase TRIB1. Science Signaling, 2018, 11, .	1.6	46
18	Effect of Aromatase Inhibition on Functional Gene Modules in Estrogen Receptor–Positive Breast Cancer and Their Relationship with Antiproliferative Response. Clinical Cancer Research, 2014, 20, 2485-2494.	3.2	39

ANITA K DUNBIER

#	Article	IF	CITATIONS
19	Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer. Breast Cancer Research, 2012, 14, R78.	2.2	38
20	Hereditary diffuse gastric cancer. Advances in Cancer Research, 2001, 83, 55-65.	1.9	35
21	Close and Stable Relationship between Proliferation and a Hypoxia Metagene in Aromatase Inhibitor–Treated ER-Positive Breast Cancer. Clinical Cancer Research, 2011, 17, 3005-3012.	3.2	31
22	Recent data on intratumor estrogens in breast cancer. Steroids, 2011, 76, 786-791.	0.8	28
23	A PAM50-Based Chemoendocrine Score for Hormone Receptor–Positive Breast Cancer with an Intermediate Risk of Relapse. Clinical Cancer Research, 2017, 23, 3035-3044.	3.2	28
24	Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor–positive breast cancers. Breast Cancer Research, 2014, 16, 447.	2.2	25
25	N-Terminal E-Cadherin Peptides Act as Decoy Receptors for Listeria monocytogenes. Infection and Immunity, 2003, 71, 1580-1583.	1.0	19
26	Differences in the Transcriptional Response to Fulvestrant and Estrogen Deprivation in ER-Positive Breast Cancer. Clinical Cancer Research, 2014, 20, 3962-3973.	3.2	19
27	A novel diffuse gastric cancer susceptibility variant in E-cadherin (CDH1) intron 2: A case control study in an Italian population. BMC Cancer, 2008, 8, 138.	1.1	13
28	Impact of Estrogen Deprivation on Gene Expression Profiles of Normal Postmenopausal Breast Tissue <i>In vivo</i> . Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 855-863.	1.1	10
29	New and translational perspectives of oestrogen deprivation in breast cancer. Molecular and Cellular Endocrinology, 2011, 340, 137-141.	1.6	9
30	Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer. Breast Cancer Research, 2015, 17, 35.	2.2	8
31	Structure vs. Function of TRIB1—Myeloid Neoplasms and Beyond. Cancers, 2021, 13, 3060.	1.7	7
32	Variable expression quantitative trait loci analysis of breast cancer risk variants. Scientific Reports, 2021, 11, 7192.	1.6	6
33	Progress in aromatase research and identification of key future directions. Journal of Steroid Biochemistry and Molecular Biology, 2010, 118, 311-315.	1.2	4
34	Increased gene expression variability in BRCA1-associated and basal-like breast tumours. Breast Cancer Research and Treatment, 2021, 189, 363-375.	1.1	3
35	Oestrogen deprivation induces chemokine production and immune cell recruitment in in vitro and in vivo models of oestrogen receptor-positive breast cancer. Breast Cancer Research, 2021, 23, 95.	2.2	3
36	Aromatase Inhibitor Resistance via Non-endocrine Signalling Pathways. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 169-190.	0.1	2

IF

CITATIONS

ARTICLE

Gastric Cancer: Inherited Predisposition. , 2002, , 253-258.